Biotech's great run has been achieved despite a number of macroeconomic events along the way that periodically spooked the general markets, but left the confidence in the industry largely unscathed. Although the sector has managed to shrug off those stock market perturbations, it was a different story at the end of second quarter as the markets headed south. Read More
Despite financial market turbulence toward the end of the second quarter, it did not derail the ability of biotechs to raise capital to fuel their programs although the tsunami of cash that flooded into their coffers during the first quarter did slow down considerably. Read More
The torrid pace set by global private companies in the first quarter of the year, raising just shy of $2.4 billion, did not slow down in the second quarter – in fact, it increased. Thanks to several marquee deals, global private companies enjoyed another highly successful period attracting venture investments that totaled around $2.5 billion, eclipsing the record amount raised in the first quarter. Read More
